Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Burke Website

Terrence R. Burke Jr., Ph.D.

Selected Publications

1)  Liu F, Park JE, Qian WJ, Lim D, Gräber M, Berg T, Yaffe MB, Lee KS, Burke TR.
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel.
Nat. Chem. Biol. 7: 595-601, 2011.
2)  Liu F, Park J, Qian W, Lim D, Scharow A, Berg T, Yaffe MB, Lee KS, Burke TR.
Identification of High Affinity Polo-like Kinase 1 (Plk1) Polo-box Domain Binding Peptides Using Oxime-Based Diversification.
ACS Chem Biol. 7: 805-10, 2012.
3)  Qian W, Liu F, Burke TR.
Investigation of unanticipated alkylation at the N(TT) position of a histidyl residue under Mitsunobu conditions and synthesis of orthogonally protected histidine analogues.
J. Org. Chem. 76: 8885-90, 2011.
4)  Nelson CG, Burke TR.
Samarium iodide-mediated Reformatsky reactions for the stereoselective preparation of beta-hydroxy-gamma-amino acids: synthesis of isostatine and dolaisoleucine.
J. Org. Chem. 77: 733-8, 2012.
5)  Zhao XZ, Smith SJ, Métifiot M, Johnson BC, Marchand C, Pommier Y, Hughes SH, Burke TR.
Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency Against Cells Harboring Raltegravir-Resistant Integrase Mutants.
J. Med. Chem. 57: 1573-1582, 2014.
6)  Zhao XZ, Smith SJ, Metifiot M, Marchand C, Boyer PL, Pommier Y, Hughes SH, Burke TR.
4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing Compounds Having High Potency Against Raltegravir-Resistant Integrase Mutants of HIV-1.
J. Med. Chem. 2014.
In Press. [Journal]
7)  Bryant K, Yan Z, Gregory S, Angelova M, Dreyfus D, Zhao X, Coen D, Burke TR, Knipe D.
HIV integrase inhibitors block replication of alpha, beta, and gamma herpesviruses.
mBio. 2014.
In Press. [Journal]
8)  Qian WJ, Lai CC, Kelley JA, Burke TR.
Design and Synthesis of Fmoc-Thr[PO(OH)(OPOM)] for the Preparation of Peptide Prodrugs Containing Phosphothreonine in Fully Protected Form.
Chem. Biodivers. 11: 784-91, 2014.
9)  Zhang M, Luo Z, Liu H, Croce CM, Burke TR, Bottaro DP.
Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist.
Leukemia. 28: 948-951, 2014.
10)  Métifiot M, Maddali K, Johnson BC, Hare S, Smith SJ, Zhao XZ, Marchand C, Burke TR, Hughes SH, Cherepanov P, Pommier Y.
Activities, crystal structures and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase.
ACS Chem. Biol. 8: 209-217, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 6/24/2014.